OliX Pharma Announces New Data at the World Congress for Hair Research

OliX Pharmaceuticals, a Korean biopharmaceutical company that focuses on developing RNAi therapies, has recently announced some results from its hair loss indication OLX104C (an asymmetric siRNA targeting androgen receptor therapy) at the 13th World Congress for Hair Research (WCHR 2024). A collaborator working with OliX on research on OLX104C, Dr Jonghyun Won, presented the data on the hair loss inhibition effect of the drug and the long-term impact of the drug in dermal papilla cells, human hair follicles, and mouse models.

While no results have been discussed in any press releases, they have been described as “promising“, so we hope to get some published news soon. 

The presentation at the WCHR was titled “Efficacy of Asymmetric siRNA Targeting Androgen Receptor for the Treatment of Androgenetic Alopecia”.